Inoviq Ltd · ASX:IIQ
Inoviq — Shareholder Meeting (November 2024)
27 slides from Inoviq's shareholder meeting presentation, Nov 28, 2024
Slide 1: AGM Presentation
AGM Presentation 28 November 2024 Next-generation diagnostics and therapeutics ASX: IIQ
Slide 2: Important notice and disclaimer
Important notice and disclaimer This presentation has been prepared by INOVIQ Limited (“INOVIQ” or the “Company”) Actual results, performance or achievements could be significantly different from those based on information available to it as at the date of this presentation. This presentation expres
Slide 3: INOVIQ Overview
INOVIQ Overview| Next generation diagnostics and therapeutics Financial information (ASX:IIQ) Ordinary shares1 111,526,702 Exosome Disruptive Products Listed / Unlisted options1 9,378,913 / 7,824,889 powered technology in market 52-week H/L1 A$0.92-0.42 Share price1 A$0.44 Next-gen exosome Proprieta
Slide 4: Vision
Vision| Leading exosome diagnostics and therapeutics company Strategic Focus Core Technologies Exosome Platform SubB2M Technology Next-generation exosome diagnostics and therapeutics NETs immunoaffinity, magnetic Proprietary neu5Gc probe for bead-based EV isolation for cancer improved cancer detecti
Slide 5: FY24 Achievements
FY24 Achievements| Strong development & commercial progress Commercial Exosome Programs • Jul-23 EXO-NET® Global Joint Marketing Agreement with Promega • Aug-23 EXO-OC test data demonstrating equivalence of EXO-NET® • Sep-23 EXO-NET® Services License and Supply Agreement with isolated exosomes from
Slide 6: EXO-NET Commercial Progress
EXO-NET Commercial Progress • Total # customers: as at 31st Oct-24 • Promega partnership expected to be a key driver of EXO-NET revenues • First order received Jun-24, with 33 customers won in 4 months Customer Profile # (> 8/m or 2/w) from US, EU and Asia type • Applications: Oncology, Neurology, C
Slide 7: Exosome Platform
Exosome Platform Research Tools Diagnostics Therapeutics 7
Slide 8: Exosomes
Exosomes| Significant diagnostic and therapeutic potential • Exosomes are small vesicles released by cells that perform key roles in intercellular communication, immune regulation and disease progression DNA ➢ Exosomes carry molecular cargo (DNA, RNA, proteins and lipids) that act as RNA cell messen
Slide 9: EXO-NET
EXO-NET®| Pan-exosome isolation product in-market and generating revenue Best-in-class EXO-NET pan-exosome capture tool (research use only) in-market and surface generating revenue antigens Enables biomarker discovery and diagnostic development for screening, liquid biopsies and companion diagnostic
Slide 10: NEURO-NET
NEURO-NET | Brain-derived exosome isolation now validated & available Custom NEURO-NET exosome capture tool for isolation of brain-derived exosomes NEURO-NET identifies differently-expressed proteins from Alzheimer's Disease plasma Designed using proprietary antibody combination that isolates exosom
Slide 11: Exosome Diagnostics
Exosome Diagnostics| Academic collaboration validating EXO-NET Collaboration with UQ to develop blood-based exosomal screening test for ovarian cancer1 ROC comparison analysis between OCRF-7 • UQ1 OCRF-7 test developed in a retrospective case- and CA-125 in the same cohort of patients control study
Slide 12: Ovarian Cancer screening test
Ovarian Cancer screening test| Path-to-market • #8 cancer in women & deadliest gynaecological cancer • 314k new cases of ovarian cancer worldwide pa1 Development Path Ovarian Cancer • 0.25% of population has Hereditary Breast and Ovarian Cancer syndrome2 Feasibility Completed • No approved test for
Slide 13: Exosome Therapeutics
Exosome Therapeutics| Next-gen cell-free therapy • The therapeutic effects of Cell Therapy are mediated by Second-line tx Blood cancers CAR-exosome exosomes interacting with host cells Next-gen cell-free therapy Standalone or combination Follow-on to autologous therapy CAR-T therapy • Cell-Free Ther
Slide 14: CAR-Exosomes
CAR-Exosomes| Allogenic EV-based therapy with multiple advantages Engineer Establish In vivo Activate and In vitro Phase I/II immortalized Master Cell Isolate EVs animal IND expand efficacy Clinical Trials CAR-cells Bank studies ✓ Improved efficacy in solid tumours due to ability to infiltrate TME b
Slide 15: CAR-T-EVs
CAR-T-EVs| A promising alternative to cell-based therapies CAR-EV generation, enrichment, EV characterisation and functional readout • CAR-T cells targeting EGFR were cultured and EVs isolated from cell-conditioned medium by ion- exchange chromatography (EXO-ACE ) • EGFR targeting CAR-EVs reduced MC
Slide 16: CAR-Exosome Therapy
CAR-Exosome Therapy| Development path Program EXO-ACE In Vivo Selection First Patient Approval CAR EV Isolation Studies of CRO Dose CAR-T / NK Cell In Vitro IND Regulatory Approval Development Studies Submission and Site Selection ✓Master cell ✓High purity & ✓In vitro PoC for • In vivo studies banks
Slide 17: SubB2M Cancer Diagnostics
SubB2M Cancer Diagnostics Improved cancer detection and monitoring neuraminic acid (neu5Gc) 17
Slide 18: SubB2M
SubB2M| Glycan-binding technology and scientific rationale Aberrant glycosylation (production of sugars) is a hallmark of cancer Neu5Gc is a sugar commonly found on cancer cells, but not healthy cells SubB2M is an engineered protein that specifically binds neu5Gc SubB2M is used in an immunoassay for
Slide 19: Breast Cancer monitoring test
Breast Cancer monitoring test| Path-to-market • #1 cancer in women Development Path Breast Cancer • 2.3m new cases of breast cancer worldwide pa1 • 7.8m survivors (5-year)1 Feasibility Completed • Non-invasive, earlier and more accurate tests required for monitoring breast Unmet Medical Assay Comple
Slide 20: SubB2M Breast Cancer clinical data
SubB2M Breast Cancer clinical data| Outperformed leading CA15-3 test Clinical Validation Study by Stage (2023)1 SubB2M CA15-3 vs Leading Existing Test Retrospective, case-control, clinical validation study (n=483) to Breast Cancer SubB2M Roche evaluate breast cancer detection by stage All Stages CA1
Slide 21: Outlook & Catalysts
Outlook & Catalysts 4 % ras Rae _ ise ST 4 o =INOVIQ
Slide 22: Outlook
Outlook| Positioned for growth Proprietary exosome platform with multiple research, diagnostic and therapeutic applications Global distribution partner for EXO-NET research tools to drive revenue growth Multiple evaluations underway for EXO-NET / NEURO-NET exosome isolation, biomarker discovery and
Slide 23: Future catalysts
Future catalysts| Developing better healthcare solutions EXO Research Tools TEXO-NET validation data Commence EXO-OC test EXO-OC test biomarker EXO-Dx-OC clinical validation for Exosome Program validation data ovarian cancer screening Commence exosome EXO-Dx- Exosome diagnostic diagnostic developmen
Slide 24: Contacts
Contacts David Williams Dr Leearne Hinch BVMS MBA Non-Executive Chairman Chief Executive Officer e. dwilliams@kidder.com.au e. lhinch@inoviq.com Prof Gregory Rice PhD MHA Mark Edwards CA B Acc Chief Scientific Officer CFO & Company Secretary e. grice@inoviq.com e. medwards@inoviq.com INOVIQ Ltd, 23
Slide 25: Appendices
Appendices 4 “ SS ras ‘ _ ise ST 4 a =INOVIQ
Slide 26: Board & Management
Board & Management| Corporate, scientific and commercial expertise DAVID WILLIAMS DR GEOFF CUMMING MAX JOHNSTON PHILIP POWELL MARY HARNEY Non-Executive Chairman Non-Executive Director Non-Executive Director Non-Executive Director Non-Executive Director Experienced biotechnology director and Healthca
Slide 27: Products & pipeline
Products & pipeline| Multi-stage diagnostics and therapeutics portfolio Product Indication and Use Development Stage Next Milestones Market Opportunity Biomarker Discovery & Diagnostics In-Market Sales Growth & EXO-NET Pan EV Capture RUO Collaborations Neurology Diagnostics Validation Research Tools